Introduction Rationale
Deep brain stimulation (DBS) has emerged as a novel neurosurgical method to treat movement disorders such as Parkinson disease, 1 essential tremor, 2-4 chronic pain, 5 Tourette syndrome, 6 and psychiatric disorders like obsessive-compulsive disorder, 7 depression, [8] [9] [10] and anorexia nervosa. 11 High-frequency stimulating electrodes are placed in one of several target areas in the brain, including the ventrolateral thalamus, subthalamic nucleus (STN), or internal segment of the globus pallidus (GPi) and periaqueductal gray matter, and are connected to an implantable pulse generator. DBS involves the delivery of precise electrical signals to specific deep anatomical structures in the central nervous system. DBS is thought to affect the firing rates and bursting patterns of neurons and, ultimately, the synchronized oscillatory activity of neuronal networks.
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Objectives
For some of the neurologic conditions just listed, several randomized controlled trials and systematic reviews have been
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Abstract
Background This umbrella review summarizes the evidence across meta-analyses regarding the effectiveness and adverse effects of deep brain stimulation (DBS). Methods Databases were searched up to March 2015 for meta-analyses of comparative trials in humans assessing the effectiveness or adverse effects of DBS. Data selection, data extraction, and risk of bias assessment were performed by two independent reviewers. Results Seven eligible systematic reviews were included assessing the use of DBS for epilepsy (n ¼ 1), obsessive-compulsive disorder (n ¼ 1), and Parkinson disease (n ¼ 5). The summary estimates were significant at p 0.05 in four meta-analyses (27%) with both fixed and random effects. One meta-analysis reported that DBS was more effective than sham in reducing the Yale-Brown Obsessive Compulsive Scale score in obsessivecompulsive disorder patients. The remaining three meta-analyses reported differences regarding mortality and depression in patients with Parkinson disease between DBS of the subthalamic nucleus and of the globus pallidus internus. Of the 15 meta-analyses, none compiled adequately robust evidence. Conclusions Although DBS has emerged as a viable surgical intervention to treat various disabling neurologic symptoms, existing studies fail to adequately support its use based on robust evidence without hints of bias.
published in the last decade but have not been evaluated systematically up to now. To evaluate the strength of evidence regarding the clinical indication for the use of DBS, we performed an umbrella review of the evidence across meta-analyses pertaining to the effectiveness or adverse effects of DBS. We aimed to assess the direction and magnitude of existing effects, as well as to evaluate whether there are hints of biases in the literature that could endanger the validity of the results.
Materials and Methods
Literature Search
Two researchers (P.N.P. and S.N.P.) independently searched Medline, Scopus, the Cochrane Database of Systematic Reviews, and the Cochrane Database of Abstracts of Reviews of Effects from inception to the end of March 2015 for metaanalyses or systematic reviews of studies investigating the effectiveness or adverse effects of DBS. ►Appendix A describes the exact literature search for each database. The references from eligible systematic or narrative reviews were also checked. The titles, abstracts, and full texts of the resulting articles were examined in detail, and discrepancies were resolved by a third researcher (J.D.).
Eligibility Criteria and Data Extraction
Articles were eligible if the authors had performed a systematic search to identify pertinent clinical trials on DBS in humans and had performed quantitative data synthesis comparing at least two experimental/control groups. We included systematic reviews on both randomized controlled trials (RCTs) and non-RCTs. Meta-analyses or systematic reviews that did not present study-specific data were excluded, but the data were requested from the corresponding author. We included meta-analyses of both binary and continuous outcomes. If an article presented separate meta-analyses on more than one eligible outcome, those were assessed separately. Whenever more than one meta-analysis existed on the same scientific question, the meta-analysis with the largest number of studies and/or the most complete reporting was selected, but we conducted sensitivity analyses to assess any differences in these duplicate meta-analyses.
From each eligible systematic review, two authors (P.N.P. and S.N.P.) abstracted independently the information on publication type, number of searched databases, search period, type of included trials, number of assessed outcomes (including measures against multiple testing), and citation counts from Google Scholar (http://scholar.google.com). We recorded if the included systematic reviews assessed the risk of bias of the individual studies and the quality of evidence according to the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach, 14 but we did not perform these procedures ourselves because that task was beyond the scope of this umbrella review. We also appraised the methodological quality of the included systematic reviews with the Assessing the Methodological Quality of Systematic Reviews (AMSTAR) tool. 15 Finally, we assessed the risk of bias of the included systematic reviews with the newly designed ROBIS tool.
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From each eligible meta-analysis, the same two authors abstracted information independently on first author, year of publication, outcome examined, number of included studies, and reported data at the individual trial level. For each of the included studies in each eligible meta-analysis, we recorded the study design (RCT or non-RCT), the number of cases (for binary outcomes), and population participants.
Assessment of Summary Effects and Heterogeneity
For meta-analyses of continuous outcomes, standardized mean differences (SMDs) were chosen as effect estimates. Binary outcomes were also transformed to SMDs to enable a synthesis of both continuous and binary outcomes together.
We estimated the summary effects using both fixed-effect and inverse variance random-effects models.
17 Fixed-effect meta-analysis relies on the assumption that a unique effect underlies every study in the meta-analysis and no heterogeneity between studies exists. A random-effects synthesis makes the assumption that individual studies are estimating different effects that are assumed to have a normal distribution. The random-effects meta-analysis is performed to estimate the mean of this distribution of effects across different studies and the uncertainty about that mean (95% confidence interval [CI]). We also calculated the 95% prediction interval (PrI) for the summary random-effects estimates that further account for heterogeneity between studies and indicate the uncertainty for the effect that would be expected in a new study examining that same association. 18 The 95% PrI shows where the true effects are for 95% of the studies from the population of studies that are synthesized or similar (exchangeable) studies that might be done in the future.
We assessed heterogeneity between studies using the p value of the chi-square-based Cochran Q test and the I 2 metric of inconsistency; this could reflect either genuine diversity or bias. The Q test is obtained by the weighted sum of the squared differences of the observed effect in each study minus the fixed summary effect. 19 The I 2 metric ranges between 0% and 100% and is the ratio of variance between studies over the sum of the variances within and between studies. The 95% CIs around I 2 were calculated according to the noncentral chi-square approximation of Q.
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A sensitivity analysis according to the basic study design of included trials 21 was conducted with mixed-effects subgroup analysis (random-effects meta-regression) and by calculating the ΔSMDs (difference in SMDs) and the associated 95% CIs. An iterative residual maximum likelihood algorithm was used for the estimation of between-study variance because of its performance, 22 and the Knapp-Hartung modification 23 was used for the calculation of the ΔSMDs that accounts for the uncertainty in the heterogeneity estimate. 24 The effect magnitude both for SMD and ΔSMD was conventionally judged as 0.2 ¼ small effect, 0.5 ¼ medium effect, and 0.8 ¼ large effect. 25 The cut-off of SMD or ΔSMD > 0.8 was used to construct contours of large effect magnitude in all forest plots.
than large studies. Small study effects can indicate publication bias or other reporting biases, but they can also reflect genuine heterogeneity, chance, or other reasons for differences between small and large studies. 26 We used the regres- 
Associations Meeting Further Criteria
We further identified associations for which the summary fixed-and random-effects estimates showed strong evidence of significance (p < 0.001; a threshold that has been suggested to substantially reduce the number of false-positive findings 29 ); were based on evidence from > 500 cases for binary outcomes or from > 5,000 participants for continuous outcomes 30 ; did not have large heterogeneity between studies (I 2 < 75%); their 95% PrI excluded the null value; and had no evidence of small study effects (from the Egger test). All calculations were performed in STATA software v.12 (StataCorp, College Station, Texas, United States). All p values are two sided, and statistical significance is set at 5% for all tests, except for heterogeneity and Egger tests (10%). Although multiple p values are reported in this umbrella review, no correction or adjustment was performed because we aimed to summarize the results of the included articles.
Results
Characteristics of Included Systematic Reviews
A total of 100 hits were received from the electronic literature search; another three articles were added manually (►Fig. 1). After removal of duplicates, screening, and application of the inclusion criteria, a total of seven systematic reviews were included in this umbrella review [31] [32] [33] [34] [35] [36] [37] (►Table 1; ►Appendix B). A total of 18 reviews with potentially eligible meta-analyses were excluded from the umbrella review because they did not include conventional pairwise meta-analytic comparisons but performed averaging among studies, pooled single group estimates, or generated control group data from expert opinions. Missing data at the trial level were requested in two instances (►Appendix B), but no answer was received and the reviews were excluded. Chambers and Bowen 32 performed metaanalysis of both DBS and vagus nerve stimulation at various stimulation degrees for the treatment of epilepsy, but only the subgroup on DBS (one single trial) is included in this umbrella review. Four reviews were published in scientific journals, [32] [33] [34] 36 one was published in the Cochrane Library, 37 and the remaining two were posters from a scientific congress (►Appendix B). 
Risk of Bias and Methodological Adequacy
Of the seven included systematic reviews, four of them [32] [33] [34] 37 
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The quality of evidence (strength of recommendations) from the performed meta-analyses was assessed with the GRADE approach in only 2 of 7 reviews 32,37 (29%). The strength of recommendations from the one review comparing on versus off DBS for drug-resistant epilepsy was low, due to imprecision and hints of publication bias. 32 The strength of recommendations from the review comparing DBS with sham ranged from very low to high. Imprecision, confounding due to a missing washout period in crossover trials, and the absence of drug regulation were the reasons to downgrade the quality.
The methodological adequacy of the included reviews was appraised with the AMSTAR tool. This appraisal was limited only to reviews published in journals or in the Cochrane Library because the two reviews in poster format did not provide adequate information. The AMSTAR scores for the five reviews ranged from 2 to 11 (►Appendixes C. D), with only the Cochrane Review scoring the maximum of 11 points. The main shortcomings were lack of a priori design, incomplete reporting of included/excluded studies, and missing statements for possible conflicts of interest.
The risk of bias of the included reviews was appraised with the ROBIS tool. As with the appraisal of methodological adequacy, risk of bias was assessed only in reviews published in journals or in the Cochrane Library. Four of five reviews were judged to show a high risk of bias (►Fig. 2; ►Table 2; ►Appendix E), with only the Cochrane Review showing a low risk of bias.
Summary Effect Sizes
A total of 15 unique meta-analyses were extracted from the 7 included reviews: 4 meta-analyses (from one review As far as the efficacy of DBS is concerned, the results of the meta-analyses were significant at the p 0.05 level in one instance, both with fixed-and random-effects models: absolute effectiveness of DBS compared with sham in patients with obsessive-compulsive disorder. The results of the largest study, compared with the pooled effect, were almost the same in all cases (meta-analyses 3, 8, and 10). The 95% PrI did not exclude the null value in any case, indicating that no clinical recommendations can be made on the basis of existing evidence. Regarding the comparative effectiveness of DBS, the results of the meta-analyses were significant at the p 0.05 level in three instances, both with fixed-and random-effects models, regarding the effectiveness against depressive symptoms or minimization of mortality with DBS use for Parkinson disease according to the stimulated target. The results of the meta-analyses were significant at the p < 0.001 level with both models regarding the nonmotor symptoms of Parkinson disease, assessed with the Beck Depression Inventory-II. ►Table 4 also shows the effect of the largest study included in each meta-analysis. The results of the largest study, compared with the pooled effect, agreed in direction but were more conservative in four cases (meta-analyses 1, 2, 3, and 5), were almost the same in three cases (meta-analyses 4, 6, and 7), and were on the opposite direction in three cases (meta-analyses 8 and 9). The 95% PrI excluded the null value only for the metaanalysis of post-DBS depression severity compared with the DBS target (meta-analysis 3).
Overlap Among Meta-Analyses
Overlaps among meta-analyses existed only regarding the use of DBS in patients with Parkinson's disease. Overlaps existed among three reviews for three studied outcomes, that is, the 
Heterogeneity and Small Study Effects
The Q test showed significant heterogeneity (p 0.10) for two meta-analyses (Table 4) , both with moderate to high inconsistency (I 2 between 50% and 75%). Another meta-analysis had moderate inconsistency (52%), and the rest had I 2 < 50%.
Uncertainty around the heterogeneity estimates was often large, as reflected by wide 95% CIs of the I 2 . In one of the meta- Fig. 2 ROBIS risk of bias of the included systematic reviews. Assessment of the risk of bias regarding the four domains covered by the ROBIS tool: the study eligibility criteria, the identification and selection of studies, the data collection and study appraisal, and the synthesis of findings. Darker colors indicate overall risk of bias rating; lighter colors concern judgments. analyses with significant heterogeneity (►Table 4; metaanalysis 8), the authors conducted a sensitivity analysis by removing the trial with the largest effect, thereby reducing the heterogeneity. However, no clinical reasoning was provided for this choice. Sensitivity analyses according to the study design of the included trials (RCT or non-RCT) were possible in four meta-analyses from two systematic reviews 31,35 that included both RCTs and non-RCTs (►Appendix H). In three of four meta-analyses, non-RCTs gave hints of effect overestimation, which was however nonsignificant in all cases (p > 0.05). However, the differences in SMDs ranged between 0.07 and 0.74, the latter approaching the cut-off for large effect magnitude (0.8).
There was no evidence of small study effects, except for one case where the Egger test was significant (►Table 4; p ¼ 0.041). In this meta-analysis the change in semantic verbal fluency in Parkinson patients after STN or GPi DBS was more conservative in the larger studies.
Associations Meeting Further Criteria
Of the 15 included meta-analyses, none fulfilled all the criteria set (►Appendix I), and the greatest problem was the limited number of studies/patients included.
Discussion Principal Findings and Possible Explanations
We performed an umbrella review to examine the existing evidence from meta-analyses on the use of DBS in patients with various disabling neurologic symptoms. Although 15 meta-analyses were finally included, most reported on nominally nonsignificant effects, both pertaining to the effectiveness of DBS and to the minimization of adverse effects. Only a small minority of meta-analyses (n ¼ 4) reported on statistically significant effects, but none of these was based on robust epidemiological evidence.
DBS for Obsessive-Compulsive Disorder
DBS was reported to be more effective in alleviating the disease symptoms of patients with obsessive-compulsive disorder (as measured by the Yale-Brown Obsessive Compulsive Scale) compared with sham stimulation. 33 Although the effects were consistent across all five included studies and the random-effects pooled summary indicated a large effect magnitude, clear indications of imprecision existed that resulted in uncertainty in the estimates. This can be remedied, however, by the inclusion of additional RCTs on this subject that might strengthen the quality of clinical recommendations for the use of DBS in obsessive-compulsive patients. It has been reported that DBS targeted at the nucleus accumbens of patients with obsessive-compulsive disorder appears to release dopamine in the striatum, which is associated with increased plasma levels of homovanillic acid and improved clinical symptoms. This suggests that DBS may compensate for a defective dopaminergic system. These changes hint at a causal role of dopamine in the therapeutic efficacy of DBS and agree with previous insights on the role of dopamine in obsessive-compulsive disorder. 38, 39 But further research is needed to confirm this. 40 Finally, as suggested by the American Society for Stereotactic and Functional Neurosurgery, it is imperative that electrophysiologic, morphological (neuroimaging), functional, or clinical predictive factors are developed that will enable to identify the most appropriate candidates for this procedure.
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DBS for Parkinson Disease
One of the most interesting findings of this umbrella review is that no meta-analysis on the efficacy of DBS for Parkinson disease was identified and included. Regarding comparative effectiveness, recent studies reported no significant difference between STN and GPi DBS in improving motor control in patients with Parkinson disease, 42, 43 which is the main outcome of interest in Parkinson disease. However, existing evidence indicates that significant differences exist between STN or GPi DBS in patients with Parkinson disease, as far as mortality or depression are concerned.
34-36 STN DBS was associated with higher patient mortality than GPi DBS (p < 0.01). However, the authors of the meta-analysis reported that because most deaths were due to postoperative complications not directly related to DBS, confounding cannot be excluded. 35 Additionally, it must also be noted that nonRCTs were also included in this meta-analysis, which might have introduced further bias, 21 and clear signs of imprecision were also present. Furthermore, STN DBS was also associated with a greater incidence of depression and with more severe depression, as measured with the Beck Depression Inventory-II, compared with GPi DBS. 34, 36 Thus GPi DBS may be beneficial to treat severe nonmotor mood symptoms than STN DBS. Some of these nonmotor symptoms can even predate the motor problems [44] [45] [46] and are often more disabling and resistant to treatment than motor symptoms, as they are key determinants of quality of life. However, due to the uncertainty around the existing results that originate from imprecision, no clear distinction between the pros and cons of STN and GPi DBS can be made, and further studies are needed to form robust clinical recommendations.
Strengths, Weaknesses, and Future Research
Several limitations and caveats should be considered in the interpretation of our findings. First, we included only studies used in certain published meta-analyses and thus might have missed some individual studies if those were not identified in the original systematic searches. Second, data at the trial level were missing for some meta-analyses and were therefore excluded. Third, most of the included systematic reviews presented serious methodological inadequacies, 47 like inadequate justification for the statistical model 48 and metric used, 49 incomplete assessment of clinical and statistical heterogeneity, 47 and partial risk of bias assessment at the individual trial or meta-analysis level. Finally, funnel plot asymmetry was consistently investigated with the Egger test for all meta-analyses, although < 10 trials were included in every case, 26 according to previous umbrella reviews. 30, 50, 51 Future research should focus on planning and conducting blinded RCTs with a priori sample size calculations that will enable an adequately powered assessment of the benefits and harms of DBS for its various neurologic indications. Furthermore, there is a great number of published RCTs on the use of DBS for various conditions that have not yet been systematically appraised including refractory partial seizures, 52 medication-refractory cervical dystonia, 53 essential tremor,
54
Alzheimer disease, 55 and treatment-resistant depression.
56
These could be the focus of future systematic reviews.
Conclusions
Although use of DBS for the treatment of various disabling neurologic symptoms has been studied to some effect, firm universal conclusions about either its efficacy or comparative effectiveness cannot be drawn. There is limited evidence that DBS is effective in reducing symptoms in obsessive-compulsive disorder patients and that GPi DBS is more beneficial than STN DBS in reducing nonmotor symptoms in Parkinson patients. However, these associations do not meet the epidemiological criteria for credibility that were set for this umbrella review, and further well-designed studies are needed. 
